Eli Lilly and Company (NYSE:LLY) Shares Purchased by Apollon Wealth Management LLC

Apollon Wealth Management LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 50.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 13,679 shares of the company’s stock after purchasing an additional 4,609 shares during the quarter. Apollon Wealth Management LLC’s holdings in Eli Lilly and Company were worth $7,974,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $26,000. Thompson Investment Management Inc. purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at $27,000. Optiver Holding B.V. acquired a new position in shares of Eli Lilly and Company in the third quarter worth $36,000. Family CFO Inc purchased a new stake in shares of Eli Lilly and Company during the third quarter worth $40,000. Finally, O Brien Wealth Partners LLC boosted its position in Eli Lilly and Company by 70.5% during the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock valued at $44,000 after purchasing an additional 31 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY traded up $11.09 during mid-day trading on Tuesday, hitting $777.77. The company’s stock had a trading volume of 2,842,407 shares, compared to its average volume of 3,088,457. The stock’s 50-day moving average is $760.96 and its two-hundred day moving average is $673.52. The firm has a market capitalization of $739.20 billion, a PE ratio of 114.55, a price-to-earnings-growth ratio of 1.45 and a beta of 0.37. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a one year low of $419.80 and a one year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the prior year, the firm earned $1.62 EPS. The business’s revenue was up 26.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 13.82 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date is Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio is 76.58%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on LLY shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 target price (up from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday, April 30th. Citigroup raised their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Bank of America boosted their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $757.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.